Oraya Therapeutics

Setting Our Sights On Your Sight

Of all our senses, our sight is widely regarded as the richest and most complex. Yet all too often we take it for granted. And for those who suffer from wet AMD, or age-related macular degeneration, it can have devastating consequences leading to severe vision loss.

Today, there is a new option for the treatment of wet AMD. Developed by Oraya Therapeutics, Inc., the breakthrough Oraya Therapy offers physicians and patients a non-invasive approach to treating wet AMD.

Intended as a one-time, non-invasive procedure, Oraya Therapy uses highly targeted, low-voltage X-rays to inhibit and prevent the growth of abnormal blood vessels under the macula (choroidal neo-vascularization) that is most often associated with wet AMD. Oraya Therapy is considered a first line treatment designed to maintain or improve vision while reducing the required number of intravitreal anti-VEGF injections. Recent clinical studies have demonstrated a 32% reduction in the injection burden with the potential for certain patients to experience more than a 50% drop in their need for anti-VEGF medications.

An Evolving Treatment Landscape

In 2006, the treatment of wet AMD shifted dramatically with the introduction of ranibizumab (Lucentis®), the first widely effective FDA-cleared injectable anti-VEGF treatment. Anti-VEGF drugs work by targeting VEGF (Vascular Endothelial Growth Factor), a protein involved in causing new blood vessel formation. Prior to the introduction of these drugs, there were no truly successful therapies. While the efficacy of anti-VEGF compounds has prolonged and saved the eyesight of millions of patients worldwide, it has also placed a huge new burden on patients who require costly, regular injections, as well as on the ophthalmic practice and on the healthcare systems.

Understandably, the availability of anti-VEGF therapy is restricted in many areas of the world, due to budget or capacity constraints, leading to compromised vision outcomes. In the major emerging economies, the existing therapies are neither practical nor affordable due to costs, the burden on the healthcare systems, and the ability of patients to access care. Additonally, although greatly beneficial in stablizing the progression of wet AMD, and decreasing resulting vision loss, the use of anti-VEGF agents carries significant known risks, such as infection (endopthalmitis), increase in intraocular pressure (glaucoma), stroke and others.

Oraya Therapeutics set out to change that situation with an innovative, exciting new treatment option, Oraya Therapy.

Learn more about AMD.

Back To Top

© 2016 All rights reserved. Oraya Therapeutics, Inc. The IRay® is a CE-marked medical device. The IRay is not available for sale in the United States. For additional details, including safety and risk information, please see the ORAYA THERAPY section of this website. Oraya, Oraya Therapy, IRay and I-Guide are either trademarks or registered trademarks of Oraya Therapeutics, Inc. in the United States and other countries.